Dr Reddy’s Laboratories Ltd has launched Docetaxel injection, a therapeutic equivalent of Taxotere, in the US market. The Hyderabad-based company had earlier obtained approval for the same from the US Food and Drug Administration.
It is indicated for the treatment of certain types of cancers. The brand and generic had sales of $218 million in the US for the most recent 12 months ending in September 2014, according to IMS Health, Dr Reddy’s said in a release.
Docetaxel injection is available in single dose, one vial formulation that does not require a prior dilution and is ready to add to the intravenous infusion solution.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.